Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results